Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Osteoporosis Drugs Market Size & Trends

The global osteoporosis drugs market size was valued at USD 14.74 billion in 2023 and is projected to grow at a CAGR of 3.5% from 2024 to 2030. The growing prevalence of osteoporosis in the population is a significant factor fueling the growth of the osteoporosis drugs market. These drugs are used in treating patients dealing with disease and fractures, the geriatric population suffering from osteoarthritis, and women with postmenopausal disorders.

Some factors that usually increase the risk of disease are a family history of osteoporosis, rheumatoid arthritis, and the long use of medications that impacts negatively hormone levels or the strength of bone such as oral steroids propels growth. Moreover, an increase in healthcare investments for discovery and drug enhancement and development aligned with a rise in awareness of drugs available for treating osteoporosis, are some of the aspects influencing osteoporosis market expansion.

The significance of early detection and treatment of osteoporosis has played a role in the market expansion. Furthermore, developments in pharmaceutical research, including the emergence of innovative treatments and precise drug delivery mechanisms, have continued to drive market growth. Furthermore, technological developments have significantly improved the quality of healthcare services that are available to the aging population. These advancements have made healthcare more reachable, efficient, and tailored. Integrating technology with healthcare has upgraded the management of chronic conditions and enabled early interference and preventive care.

Drug Class Trends & Insights

Based on drug class, the market is dominated by branded drugs. The branded medications fall under different categories such as bisphosphonates, parathyroid hormone therapy, calcitonin, selective estrogen receptor modulators (SERM), rank ligand inhibitors, and others. Due to the increased investment by major players in the research and development of innovative drugs, branded medications are expected to be the top-selling products. Branded medications are safeguarded by patents, and possess certain advantages compared to generic medications as a result of marketing strategies, brand loyalty, and governmental regulations. The promotion of branded drugs is extensive leading to heightened awareness and impacting prescription choices. Patients may opt for well-known branded drugs, even when generics are an option. Several nations have restrictions on the availability of generic drugs.

The generic drug class are poised to grow at a CAGR of 4.9% in the forthcoming years. As patents for branded drugs expire, generic versions are becoming more prevalent, leading to significant price decreases. The rising awareness of cost-effective generic drugs among patients and healthcare providers is fueling their increasing popularity in the osteoporosis drugs market, primarily due to their lower costs and the elimination of research and patent expenses. Government regulations that promote the utilization of generics, including mandates in public healthcare facilities, are also contributing to price reductions and heightened demand.

Type Insights &Trends

The bisphosphonates led the segment growth as these drugs are well-established for their efficacy and are extensively used in the treatment of osteoporosis. Bisphosphonates, such as alendronate, risedronate, and zoledronic acid, operate by slowing down the process of bone breakdown, ultimately reducing the risk of fractures, which are prominent factors for increased demand for this drug.

Rank ligand Inhibitors is projected to attain a CAGR of 5.4%. These medications are employed in the treatment of bone metastasis by functioning as a chemoattractant to the bone for tumor cells that possess its receptor.The substantial rise in growth potential realized may be due to positive patient outcomes connected with rank ligand inhibitors. Rank ligand inhibitors can also be employed in combination with other medications to produce a synergistic effect in the overall treatment regimen. This particular factor is also expected to be a key driver of lucrative opportunities. Other benefits associated with rank ligand inhibitors, such as reduced bone cell turnover and increased bone mineral density, indicate a high demand.

Distribution Channel Insights

The retail pharmacy exhibited accounted for a dominant growth drive by factors such as the growing number of geriatrics and an increasing prevalence of age-related health conditions. The retail sector in pharmaceutical distribution and the osteoporosis drugs market plays a vital role in availing such medications, for older patients to seek healthcare.

However, online pharmacies are experiencing significant growth in the distribution of geriatric medicine, with a CAGR of 5.2% over the forecast period. One of the main factors for the market growth is patients now have a practical and economical option for purchasing osteoporosis medications from online pharmacies. With the benefit of lower prices and a variety of brand-name and generic drugs, patients can discover budget-friendly remedies. In addition, the confidentiality policies and 24/7 availability of online pharmacies have improved the overall patient experience.

Regional Insights

The North America region dominated the osteoporosis drugs market, with a commanding share of 39.4% of the market in 2023. The presence of a highly developed medical and healthcare infrastructure, and an effective drug delivery system, is the primary reason for market dominance. Furthermore, substantial investments in healthcare endeavors and favorable R&D policies of the government towards osteoporosis drug applications will further boost the growth of the osteoporosis drugs market.

U.S. Osteoporosis Drugs Market Trends

The U.S. osteoporosis drugs market is dominant in North America with an increased demand for treatments and pharmaceuticals. The U.S. with its robust research and development sector, has attracted significant investments from top pharmaceutical companies. The population's high disposable income enables them to afford osteoporosis drugs and therapies easily, unlike in other countries where reliance on government programs or charitable organizations may be necessary.

The majority of health insurance plans in the U.S. include coverage for osteoporosis, ensuring greater access to essential care. The rising demand is also because of collaborative research programs conducted by major health organizations for the development of new products that continuously try to improve alternative therapies in the current market scenario.

Europe Osteoporosis Drugs Market Trends

Europe osteoporosis drugs market is growing significantly with a high awareness of geriatric medications and the implementing utilization of robot-assisted surgical processes. The market will grow at a significant rate in projected years. This can be ascribed to the increasing approvals for several medications by the European Medicines Agency, the growing numbers of drug manufacturers, the upward shift of healthcare in the region for contributing in terms of GDP & increasing elderly population has led to market growth.

The UK osteoporosis drugs market is backed by the rising prevalence of the disease and an increasing emphasis on developing innovative therapies with improved efficacy and safety segments. This is generally boosted by the growing prevalence of osteoporosis, aligned with the targeted and personalized treatment options. In addition to this, advancements in biotechnology and drug delivery systems are letting the development of new drug formulations and delivery methods, providing patients with more ease and effective treatment preferences for dealing with osteoporosis.

Germany osteoporosis drugs market is driven by several factors such as the rise in the aging population, emphasis on the safety of geriatric patients, and first preference for treatment in this population. An increase in men and women aged 75 years or more has boosted the demand. In the forthcoming years, it is also projected that targeted therapies are expected to witness more demand for pediatrics and geriatrics.

Asia Pacific Osteoporosis Drugs Market Trends

Asia Pacific osteoporosis drugs market is anticipated to witness growth at 4.1% CAGR in the forecast period. The demographic shift is expected to create several opportunities. In addition, there has been a significant increase in awareness of osteoporosis and its consequences among healthcare professionals and the general public. Various initiatives by health organizations, patient advocacy groups, and pharmaceutical companies have played a crucial role in educating people about osteoporosis prevention, early detection, and available treatment options.

China osteoporosis drugs market growth has been led by different aspects such as a rapidly aging population that impacts the incidence of osteoporosis. These include the rise in the aging population, healthcare expenditure, and awareness of osteoporosis and its diagnosis. The support by the Chinese government for the enhancement of healthcare infrastructure and other important facilities fuels the market growth in upcoming years.

India osteoporosis drugs market is expected to grow significantly in the forthcoming years as India is experiencing a shift in the increasing elderly population, that are highly prone to osteoporosis. The betterment and development of healthcare facilities & availability of healthcare services have facilitated the diagnosis and treatment of osteoporosis. Moreover, private sector investments are playing a vital role in this rise. Some other factors such as deficiencies in nutrition, sedentary lifestyles, and high expectancy of life propel the need for osteoporosis drugs and medications in India.

Key Osteoporosis Drugs Company Insights

Some key companies in the osteoporosis drugs market include Amgen Inc; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; GlaxoSmithKline plc; Pfizer Inc.; Radius Health Inc.; UCB S. A.; Teva Pharmaceuticals Industries Ltd. in the market are focusing on the development of osteoporosis drugs to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

• Amgen Inc. develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicine for treating cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology conditions.

• Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent-protected prescription medicines, generic pharmaceuticals, and biosimilars.

Recent Developments

• In November 2023, Teva Pharmaceuticals announced FDA (Food and Drug Administration) approval of a generic version of Forteo in the U.S. for certain women and men with osteoporosis

• In June 2023, Pfizer Inc. announced that DUAVEE® (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy. When treating postmenopausal women with a uterus, estrogens have traditionally been combined with a progestin. This can decrease the risk of hyperplasia (the thickening of the endometrium), which may be a precursor to cancer of the uterine lining.

Osteoporosis Drugs Market Report Scope

Global Osteoporosis Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global osteoporosis drugs market report based on drug class, type, distribution channel, and region.

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Branded

  • Generic

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Bisphosphonates

  • Parathyroid Hormone

  • Calcitonin

  • Selective Estrogen Inhibitor Modulator

  • Rank Ligand Inhibitor

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • UAE

    • South Africa

    • Kuwait